Severe Vincristine-Induced Neuropathic Pain: A Case Report with Pharmacogenetic Analysis and Literature Review

References

• Uittenboogaard A, Neutel C, Ket J, et al. Pharmacogenomics of vincristine-induced peripheral neuropathy in children with cancer: a systematic review and meta-analysis. Cancers. 2022;14:612. doi:10.3390/cancers14030612
   PubMed Web of Science ®Google Scholar
• Triarico S, Romano A, Attinà G, et al. Vincristine-Induced Peripheral Neuropathy (VIPN) in pediatric tumors: mechanisms, risk factors, strategies of prevention and treatment. Int J Mol Sci. 2021;22:4112. doi:10.3390/ijms22084112
   PubMed Web of Science ®Google Scholar
• Li GZ, Hu YH, Li DY, et al. Vincristine-induced peripheral neuropathy: a mini-review. Neurotoxicology. 2020;81:161–171. doi:10.1016/j.neuro.2020.10.004
   PubMed Web of Science ®Google Scholar
• Diouf B, Crews KR, Lew G, et al. Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia. JAMA. 2015;313:815–823. doi:10.1001/jama.2015.0894
   PubMed Web of Science ®Google Scholar
• Yang Q-Y, Hu Y-H, Guo H-L, et al. Vincristine-induced peripheral neuropathy in childhood acute lymphoblastic leukemia: genetic variation as a potential risk factor. Front Pharmacol. 2021;12. doi:10.3389/fphar.2021.771487
   Web of Science ®Google Scholar
• Weinshilboum R, Wang L. Pharmacogenomics: precision medicine and drug response. Mayo Clin Proc. 2017;92:1711–1722. doi:10.1016/j.mayocp.2017.09.001
   PubMed Web of Science ®Google Scholar
• Ceppi F, Langlois-Pelletier C, Gagne V, et al. Polymorphisms of the vincristine pathway and response to treatment in children with childhood acute lymphoblastic leukemia. Pharmacogenomics. 2014;15:1105–1116.
   PubMed Web of Science ®Google Scholar
• Lopez-Lopez E, Gutierrez-Camino A, Astigarraga I, et al. Vincristine pharmacokinetics pathway and neurotoxicity during early phases of treatment in pediatric acute lymphoblastic leukemia. Pharmacogenomics. 2016;17:731–741. doi:10.2217/pgs-2016-0001
   PubMed Web of Science ®Google Scholar
• Skiles J, Chiang C, Li C, et al. CYP3A5 genotype and its impact on vincristine pharmacokinetics and development of neuropathy in Kenyan children with cancer. Pediatr Blood Cancer. 2018;65:e26854. doi:10.1002/pbc.26854
   Web of Science ®Google Scholar
• Abaji R, Ceppi F, Patel S, et al. Genetic risk factors for VIPN in childhood acute lymphoblastic leukemia patients identified using whole-exome sequencing. Pharmacogenomics. 2018;19:1181–1193. doi:10.2217/pgs-2018-0093
   PubMed Web of Science ®Google Scholar
• Wright G, Amstutz U, Drögemöller B, et al. Pharmacogenomics of vincristine-induced peripheral neuropathy implicates pharmacokinetic and inherited neuropathy genes. Clin Pharmacol Ther. 2019;105:402–410. doi:10.1002/cpt.1179
   PubMed Web of Science ®Google Scholar
• Gutierrez-Camino A, Umerez M, Martin-Guerrero I, et al. Mir-pharmacogenetics of vincristine and peripheral neurotoxicity in childhood B-cell acute lymphoblastic leukemia. Pharmacogenomics J. 2018;18:704–712. doi:10.1038/s41397-017-0003-3
   PubMed Web of Science ®Google Scholar
• Henström M, Zucchelli M, Söderhäll C, et al. NPSR1 polymorphisms influence recurrent abdominal pain in children: a population-based study. Neurogastroenterol Motil. 2014;26:1417–1425. doi:10.1111/nmo.12401
   PubMed Web of Science ®Google Scholar
• Frost B, Lönnerholm G, Koopmans P, et al. Vincristine in childhood leukaemia: no pharmacokinetic rationale for dose reduction in adolescents. Acta paediatr. 2003;92:551–557. doi:10.1111/j.1651-2227.2003.tb02505.x
   PubMed Web of Science ®Google Scholar
• Egbelakin A, Ferguson M, MacGill E, et al. Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2011;56:361–367. doi:10.1002/pbc.22845
   PubMed Web of Science ®Google Scholar
• Dennison J, Jones D, Renbarger J, Hall S. Effect of CYP3A5 expression on vincristine metabolism with human liver microsomes. J Pharmacol Exp Ther. 2007;321:553–563. doi:10.1124/jpet.106.118471
   PubMed Web of Science ®Google Scholar
• Dennison J, Kulanthaivel P, Barbuch R, Renbarger J, Ehlhardt W, Hall S. Selective metabolism of vincristine in vitro by CYP3A5. Drug Metab Dispos. 2006;34:1317–1327. doi:10.1124/dmd.106.009902
   PubMed Web of Science ®Google Scholar
• Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet. 2001;27:383–391. doi:10.1038/86882
   PubMed Web of Science ®Google Scholar
• McClain C, Bernhardt M, Berger A, et al. Pharmacogenetic association with neurotoxicity in Hispanic children with acute lymphoblastic leukaemia. Br J Haematol. 2018;181:684–687. doi:10.1111/bjh.14678
   PubMed Web of Science ®Google Scholar
• Sims R. The effect of race on the CYP3A-mediated metabolism of vincristine in pediatric patients with acute lymphoblastic leukemia. J Oncol Pharm Pract. 2016;22:76–81. doi:10.1177/1078155214553143
   PubMedGoogle Scholar
• Guilhaumou R, Solas C, Bourgarel-Rey V, et al. Impact of plasma and intracellular exposure and CYP3A4, CYP3A5, and ABCB1 genetic polymorphisms on vincristine-induced neurotoxicity. Cancer Chemother Pharmacol. 2011;68:1633–1638. doi:10.1007/s00280-011-1745-2
   PubMed Web of Science ®Google Scholar
• Desai Z, Van den Berg H, Bridges J, Shanks R. Can severe vincristine neurotoxicity be prevented? Cancer Chemother Pharmacol. 1982;8:211–214. doi:10.1007/BF00255486
   PubMed Web of Science ®Google Scholar
• Cui Y, König J, Buchholz J, Spring H, Leier I, Keppler D. Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol Pharmacol. 1999;55:929–937.
   PubMed Web of Science ®Google Scholar
• Liu Z, Qiu M, Tang Q, Liu M, Lang N, Bi F. Establishment and biological characteristics of oxaliplatin-resistant human colon cancer cell lines. Chin J Cancer. 2010;29:661–667. doi:10.5732/cjc.009.10666
   PubMedGoogle Scholar
• Gonçalves J, Quintremil S, Yi J, Vallee R. Nesprin-2 recruitment of BicD2 to the nuclear envelope controls dynein/kinesin-mediated neuronal migration in vivo. CB. 2020;30:3116–3129.e4. doi:10.1016/j.cub.2020.05.091
   Web of Science ®Google Scholar
• Young N, Asif M, Jackson M, et al. SYNE2Biallelic missense mutations leading to nesprin-2 giant hypo-expression are associated with intellectual disability and autism. Genes. 2021;12:1294. doi:10.3390/genes12091294
   PubMed Web of Science ®Google Scholar
• Li M, Hu Y, Hu X, et al. MiRNAs and miRNA polymorphisms modify drug response. Int J Environ Res Public Health. 2016;13:1096. doi:10.3390/ijerph13111096
   PubMed Web of Science ®Google Scholar
• Stock W, Diouf B, Crews K, et al. An inherited genetic variant in CEP72 promoter predisposes to vincristine-induced peripheral neuropathy in adults with acute lymphoblastic leukemia. Clin Pharmacol Ther. 2017;101:391–395. doi:10.1002/cpt.506
   PubMed Web of Science ®Google Scholar
• Pourpre R, Naudon L, Meziane H, et al. BAHD1 haploinsufficiency results in anxiety-like phenotypes in male mice. PLoS One. 2020;15:e0232789. doi:10.1371/journal.pone.0232789
   PubMed Web of Science ®Google Scholar
• Tapmeier T, Rahmioglu N, Lin J, et al. Neuropeptide S receptor 1 is a nonhormonal treatment target in endometriosis. Sci Transl Med. 2021;13. doi:10.1126/scitranslmed.abd6469
   PubMed Web of Science ®Google Scholar